The Diagnostic Value of Preoperative Hematology Makers in the Classification and Molecular Subtypes of Newly Diagnosed High-Grade Gliomas

Xin Jia  
Zhengzhou University First Affiliated Hospital

Yixuan Zhai  
Zhengzhou University First Affiliated Hospital

Fengdong Yang  
Zhengzhou University First Affiliated Hospital

Yiming Wang  
Zhengzhou University First Affiliated Hospital

Shuxin Wei  
Zhengzhou University First Affiliated Hospital

Xinting Wei (weixinting777@126.com)  
Zhengzhou University First Affiliated Hospital  https://orcid.org/0000-0002-0482-2402

Research Article

Keywords: high-grade gliomas, preoperative hematological makers, classification, IDH mutations molecular subtypes

DOI: https://doi.org/10.21203/rs.3.rs-569387/v1

License: ☑️ This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

**Purpose:** The purpose of our study is to explore the diagnostic value of the single and combined hematological maker for the classification and isocitrate dehydrogenase (IDH)-1/2 mutations (IDH) molecular subtypes of high-grade gliomas (HGGs).

**Methods:** A total of 354 newly diagnosed HGGs patients were included in this study. Firstly, we compared the levels of hematology indicators in the classification and molecular subtypes of HGGs. Next, the correlation between the levels of hematology indicators with basic clinical features was analyzed. Finally, the diagnostic value of the single and combined hematology indicator for identifying the classification and molecular subtypes from HGGs was performed.

**Results:** The level of fibrinogen (FIB) was higher in higher grade gliomas and glioblastoma multiforme IDH wild type (GBM IDH-wt). Nutrition-related indicators such as serum albumin (ALB), albumin/globulin ratio (AGR), and prognostic nutrition index (PNI) were negatively correlated with age, whereas FIB was positively associated with age. Compared with women, men with GBM had significantly higher AGR and lower serum globulin (GLOB). We found that the best single and combined indicator for identifying GBM and GBM IDH-wt from HGGs were FIB [0.595 (0.519-0.672) and 0.615 (0.546-0.684)] and age+FIB [0.712 (0.642-0.783) and 0.726 (0.662-0.791)], respectively.

**Conclusions:** Preoperative hematological indicators have high diagnostic value for GBM and GBM IDH-wt from HGGs, especially FIB combined age.

Introduction

High-grade gliomas (HGGs) are the most common and lethal primary type of brain tumors, presenting one of the highest rates of occurrence within the tumors of the central nervous system (CNS), defined as Grade III (G3) and IV (G4) gliomas or glioblastoma multiforme (GBM) according to the 2016 World Health Organization (WHO) classification of CNS tumors\(^1\),\(^2\). HGGs individual therapies greatly vary across identifying the glioma grade and isocitrate dehydrogenase (IDH)-1/2 mutations (IDH) molecular subtypes confirmed by pathology after surgery\(^3\),\(^4\). Currently, the grade and IDH molecular subtypes of HGGs are determined by surgery or biopsy, which is invasive and traumatic to the human body. Therefore, it is necessary to establish a noninvasive method for the diagnosis of HGGs classification and IDH molecular subtypes.

At present, a large number of studies had shown that hematological indexes related to inflammation, coagulation, and nutrition had obviously predictive value in the prognosis of tumors\(^5\)-\(^7\). Meanwhile, hematology related indicators had been demonstrated to be provided with remarkable predictive value for the prognosis of gliomas, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR)\(^8\), fibrinogen (FIB), prognostic nutrition index (PNI) and albumin-to-globulin ratio (AGR)\(^9\), etc. In addition, the different levels of hematological indicators had significant diagnostic value for gliomas\(^10\).
Nevertheless, the current researches showed that the diagnostic value of hematological indicators had not yet fully included all indicators, and little is known about the grading diagnosis of HGGs.

In the present study, our goal is to identify the grade and IDH molecular subtypes of newly diagnosed HGGs based on preoperative hematological indicators related to inflammation, coagulation, and nutrition. Moreover, we also explored the correlation between these hematological indicators and basic clinical characteristics, and compared the levels of hematological indicators between HGGs of different grade and IDH molecular subtypes. We have also established the receiver operating characteristic (ROC) curve analysis to determine the best diagnostic indicators for HGGs classification and IDH molecular subtypes.

**Methods**

**Patients**

The retrospective study included patients who were confirmed with histologically as newly diagnosed G3 and G4 gliomas from January 2017 to December 2018 in the First Affiliated Hospital of Zhengzhou University (FAHZZU). The following inclusion criteria were used: 1) patients with G3 and G4 gliomas confirmed by histopathology; 2) patients with complete data of blood routine, biochemical, and coagulation results; 3) patients with IDH mutations results of histopathology; 4) patients without previous malignancy or second primary tumors. The exclusion criteria were as follows: 1) patients who had clinical evidence of liver disease, acute infection, or chronic active inflammatory diseases; 2) patients who had autoimmune diseases, hematological disorders, or anticoagulation treatment; 3) patients who had no complete hematology results; 4) patients who had previous anti-tumor treatment before admission. According to the above inclusion and exclusion criteria, 354 patients were included in the study, eventually.

**Data collection**

The baseline characteristics of all enrolled HGGs patients came from the electronic medical record system of FAHZZU. Basic clinical information was collected including gender, age at diagnosis, preoperative Karnofsky performance status (pKPS) score, preoperative epilepsy (pEPI) status, histopathological grade, IDH mutation status, and hematology indexes, such as fibrinogen (FIB, g/L), serum albumin (ALB, g/L), serum globulin (GLOB, g/L). All blood sample tests were completed by the Clinical Laboratory of FAHZZU within 2 hours after collection. The related composite indexes were calculated as follows: NLR = absolute neutrophil counts/absolute lymphocyte counts ratio; PLR = absolute platelet counts/absolute lymphocyte counts ratio; MLR = absolute monocyte counts/ absolute lymphocyte counts ratio; AGR = serum albumin/ serum globulin ratio; and PNI = albumin (g/L)+5*total lymphocyte count (10^9/L)^9.

**Statistical Analysis**
The unpaired t-test was used to compare two groups of continuous variables, and the comparison of categorical variables was performed with the Chi-square test. Multi-group comparisons were evaluated by one-way analysis of variance (one-way ANOVA), and the least significant difference t-test (LSD-t) was used for Post Hoc Multiple Comparisons. The correlation between the hematology markers and clinical features was judged by the Pearson correlation coefficient for continuous variables and the unpaired t-test. To identify the diagnostic value of the hematology markers and their combinations, the ROC analysis was used to acquire the area under the curve (AUC). The categorical variables and continuous variables were shown as frequency (percentage) and mean ± standard deviation (SD), respectively. A 2-tailed P value of <0.05 was considered to indicate statistical significance. All statistical analysis and drawing figures were performed using SPSS (version 24.0) and GraphPad Prism (version 6.01).

Results

Clinical Characteristics

There were 354 HGGs patients included in this retrospective study according to the inclusion and exclusion criteria. Table 1 summarized detailed demographic information of the research subjects. Overall, 59 (16.7%) were G3 and 295 (93.3%) were G4 of the 354 patients, respectively. All clinical features were not statistically significant (p>0.05) except for IDH (p<0.001), age (p<0.001) and FIB (p=0.034). IDH mutations tended to occur in G3 and the elderly population was more susceptible to GBM. Moreover, the level of FIB was higher in G4 compared with G3. There were 27 (45.8%) women and 32 (54.2%) men in G3 and 128 (43.4%) women and 167 (56.6%) men in G4. The existence of preoperative epilepsy (ex-pEPI) and pKPS ≤ 70 were 13 (22.0%) and 30 (50.8%) in G3 vs 46 (15.6%) and 147 (49.8%) in G4. The mean±SD of age, PLR, NLR, LMR, FIB, ALB, GLOB, AGR, PNI were 45.24±13.36 (range 4-77), 138.26±79.69, 2.79±2.24, 0.28±0.10, 2.84±0.65, 42.14±2.66, 23.68±3.82, 1.83±0.33, 51.82±4.90 and 53.76±13.32 (range 9-78), 137.18±66.27, 3.46±2.98, 0.30±0.16, 3.08±0.83, 42.14±3.66, 24.49±4.14, 1.77±0.35, 50.85±4.78 in G3 and G4, respectively.

The Levels of Hematological Indicators were Different Among IDH Molecular Subtypes

To further understand the differences in the hematological indicators of IDH molecular subtypes, we divided patients into IDH wild type (IDH-wt) and IDH mutant type (IDH-mut) according to the IDH mutation status in the study. Compared with IDH-mut, the levels of NLR (t=2.315, p=0.035) and FIB (t=3.533, p<0.001) were both increased in IDH-wt (Fig. 1a, b; Supplementary Table S1). Furthermore, we further classified patients into four subgroups based on their IDH mutation status, including G3 IDH mutant type (G3 IDH-mut), G3 IDH wild type (G3 IDH-wt), G4 IDH mutant type (G4 IDH-mut), and G4 IDH wild type (G4 IDH-wt). The results showed that only FIB was statistically significant (F=4.160, p=0.006, Fig. 1c), and further analysis showed that the levels of FIB were increased in G4 IDH-wt, compared with G3 IDH-mut (p=0.003) and G4 IDH-mut (p=0.040) (Supplementary Table S2).

The Association of Hematological Indicators With Age, Gender, pEPI, and pKPS in G3 and G4
The results showed that ALB, AGR, PNI related to nutrition were negatively correlated with HGGs. Among them, ALB (p<0.000), AGR (p<0.000), and PNI (p=0.002) were statistically significant in G4 (SupplementaryFig.S1f-h), and only PNI (p<0.000) was statistically significant in G3 (SupplementaryFig.S1d). However, the coagulation-related FIB was positively correlated with G3 (p=0.430) and G4 (p=0.003) (SupplementaryFig.S1a, e). Moreover, the inflammation-related PLR, NLR, and MLR were positively correlated with G3 but negatively correlated with G4, and they were not statistically significant (all p>0.05, SupplementaryTable S3 and Table S4).

Increased GLOB levels (25.54±3.84 vs 23.69±4.19, p<0.000) and decreased AGR levels (1.69±0.28 vs 1.83±0.38, p<0.000) were found in women, compared with men in G4 (SupplementaryTable S4). It was worth noting that there had no significant difference in hematology indexes between pEPI and pKPS subgroups (all p>0.05, SupplementaryTable S3 and Table S4).

Evaluation of Diagnostic Efficacy of Hematological Indicators in Predicting Grade and IDH Molecular Subtypes of HGGs

To find out the diagnostic value of hematology indexes in distinguishing GBM and G4 IDH-wt from HGGs, the ROC curve was performed with single indexes and combined indexes, respectively. Firstly, a single indicator was used to predict GBM and G4 IDH-wt, and the FIB had the best diagnostic value in identifying GBM from HGGs [0.595 (0.519-0.672), p=0.021] (Fig.2a) and distinguishing G4 IDH-wt from other molecular subtypes [0.615 (0.546-0.684), p=0.002] (Fig.3a). Secondly, we combined the indicators for the ROC analysis, and the results showed that age+FIB, NLR+FIB, MLR+FIB, and FIB+PNI had the highest diagnostic value among the corresponding combinations (Fig.2b,3b;2d-f,3d-f). Whether for GBM [0.712 (0.642-0.783), p=0.000] (Fig.2b) or G4 IDH-wt [0.726 (0.662-0.791), p=0.000] (Fig.3b), age+FIB was the best diagnostic index among all the combinations (Table 2). In addition, for the PLR combination group, PLR+FIB had a better diagnostic value for G4 IDH-wt [0.614 (0.545-0.683), p=0.002] (Fig.2c), but PLR+NLR had a higher diagnostic value for G4 [0.610 (0.530-0.689), p=0.008] (Fig.3c).

Discussion

Although the current pathological diagnosis of gliomas grading was the gold standard, it needed to be confirmed after surgery. For the diagnosis of HGGs grading, we need a method of preoperative prediction to guide surgical strategies and treatment more accurately. Previous studies had indicated that inflammation, including NLR, PLR, LMR, FIB, ALB, AGR and PNI had the predictive and diagnostic value for the grading and prognosis of gliomas. Our research mainly analyzed the diagnostic value of preoperative hematological indicators related to inflammation, coagulation and nutrition in the classification and IDH molecular subtypes of HGGs. In addition, we explored their correlation with age, gender, pEPI, pKPS in different grade of HGGs. Furthermore, we evaluated their levels in IDH molecular subtypes of HGGs and different grade of HGGs.
The results of this study showed that the higher grade gliomas had higher levels of NLR, MLR, FIB, ALB and GLOB, and lower levels of PLR, AGR and PNI, respectively. This result was consistent with the previous related studies\textsuperscript{11,13}, and declared more severe inflammation and worse nutritional status were present in higher grade gliomas. However, they were not statistically significant in the different grade of HGGs except FIB, which was contrary to these researches\textsuperscript{11,13}. The possible reason for this was that there were too few G3 gliomas included in this study. Only the levels of NLR and FIB were associated with IDH mutation groups, indicating that there was a link between inflammation and coagulation\textsuperscript{14}.

Furthermore, we further analyzed the relationship between hematological indicators and IDH mutation subgroups, and found that only FIB had a significant difference between G4 IDH-wt and G3 IDH-mut or G4 IDH-mut. Previous study had shown that the immune response of the tumor microenvironment was more susceptible to the modulation of IDH mutation status in lower-grade gliomas\textsuperscript{15}. This result suggested that there may be a connection between systemic and local inflammation and coagulation and immune regulation.

In our study, the levels of FIB and GLOB were positively correlated with age, and the levels of ALB, AGR and PNI were negatively correlated in the HGGs classification. However, the inflammation indicators were oppositely correlated in the HGGs grading groups. The reason for this result was the levels of FIB may reflect the critical function of FIB in an inflammatory tumor microenvironment that favors tumor progression\textsuperscript{6}. When comparing hematological indicators in gender, we found that NLR and FIB had higher levels in men. Moreover, the level of PNI had the same result, consistent with the previous study\textsuperscript{16}.

Different from other research results\textsuperscript{13,17}, the levels of PLR in our research were opposite in this comparison. There was no significant difference in the levels of hematological indicators in the pKPS and pEPI subgroups.

In the analysis of the diagnostic value of hematological indicators, single and combined indicators were explored, respectively. The level of FIB had the highest diagnostic value among the 8 hematological indicators in distinguishing GBM and G4 IDH-wt from HGGs. Our results were different from studies that found that NLR was the best diagnostic indicator, and they studied the ability of hematological indicators in distinguish GBM and G4 IDH-wt from different diseases and three grade of gliomas\textsuperscript{11,13}. In addition, as for combined indicators, age+PNI had the highest diagnostic value in the research of Wang et al\textsuperscript{13}, however, the best combined diagnostic index was NLR+MLR in the study of Zheng et al\textsuperscript{11}. The difference from them was that our research distinguished GBM and G4 IDH-wt from HGGs, and age+FIB had the highest diagnostic value among all the combined indicators. It was worth noting that grade and grade gliomas were included in their study, respectively.

This mechanism was temporarily unclear between hematological indicators and the grade of gliomas. Previous studies had declared that immune suppression induced by neutrophils may promote the progression of glioma, and some T lymphocyte subsets may inhibit it by inducing cytotoxic cell death and cytokine production\textsuperscript{18,19}. Shao et al confirmed that platelet activation contributes to tumor angiogenesis, destroys extracellular matrix and releases adhesion molecules to promote cancer cell
proliferation and metastasis, thus proving the importance of platelet activation in tumorigenesis\textsuperscript{20}. The correlation between nutritional indicators and cancer may be related to the antioxidant effect of albumin on carcinogens such as nitrosamines and aflatoxins, and the levels of GLOB may be related to the progression and metastasis of certain cancers\textsuperscript{21,22}. Moreover, albumin reflected the state of systemic inflammation by down-regulating tumor necrosis factor alpha and interleukin 6\textsuperscript{23}. Plasma fibrinogen was an important factor in inflammation and cancer expression, and had been demonstrated in vitro studies playing an important role in tumor cell proliferation, epithelial-mesenchymal transition, invasion, angiogenesis and hematological dissemination of tumor cells\textsuperscript{24-26}.

**Limitations**

Our current research has some limitations. Firstly, this study may have a selection bias because it is a single center and retrospective analysis. Secondly, the sample size of the study included in this study was small, especially G3 gliomas, and grade III and grade IV gliomas were not included. In addition, we did not have data for O6-methylguanine-DNA methyltransferase (MGMT) methylation status and telomerase reverse transcriptase (TERT) promoter status, both of which play an important role in patients with gliomas\textsuperscript{27}. Therefore, multi-center prospective studies, further molecular pathology experimental analyses, large sample researches of HGGs are required.

**Conclusions**

To sum up, the results of our research indicate that FIB plays an important role in the classification and IDH molecular subtypes of HGGs. FIB and age+FIB had the highest diagnostic value for distinguishing GBM and G4 IDH-wt from HGGs in single and combined blood indicators, respectively. Moreover, higher grade gliomas had lower levels of nutritional indicators.

**Abbreviations**

HGGs = high-grade gliomas; G3 = WHO Grade III; G4 = WHO Grade IV; GBM = glioblastoma multiforme; pEPI = preoperative epilepsy status; wit-pEPI = without preoperative epilepsy status ; ex-pEPI = existence of preoperative epilepsy status; pKPS = preoperative Karnofsky performance status score; IDH = isocitrate dehydrogenase (IDH)-1/2 mutations status; IDH-wt = IDH wild type; IDH-mut = IDH mutant type; SD = standard deviation; PLR = absolute platelet counts/absolute lymphocyte counts ratio; NLR = absolute neutrophil counts/absolute lymphocyte counts ratio; MLR = absolute monocyte counts/absolute lymphocyte counts ratio; FIB = fibrinogen; ALB = serum albumin; GLOB = serum globulin; AGR = serum albumin/serum globulin ratio; PNI = albumin (g/L) + 5 * total lymphocyte count (109/L).

**Declarations**

**Funding** No funding was received for this research.
Conflicts of interest/Competing interests The authors declare that there is no conflict of interest or competing interests.

Availability of data and material The datasets used or analyzed during the current study are available from the corresponding author on reasonable request.

Code availability Not applicable

Authors' contributions Conception and Design: WXT, ZYX, JX; Acquisition of Data: JX, WYM, WSX; Analysis and Interpretation of Data: JX; Drafting the Article: JX; Critically Revising the Article: WXT, ZYX, YFD, JX; Statistical analysis: JX; Administrative / technical / material support: WXT, ZYX, YFD; Approved the final version of the manuscript on behalf of all authors: WXT

Ethics approval This retrospective study has been approved by the Ethics Committee of the First Affiliated Hospital of Zhengzhou University.

Consent to participate Not applicable

Consent for publication Not applicable

Acknowledgments Not applicable

References

1. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. *Acta Neuropathol*. 131(6):803-820. https://doi.org/10.1007/s00401-016-1545-1

2. Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS (2018) CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. *Neuro Oncol*. 20(suppl_4):iv1-iv86. https://doi.org/10.1093/neuonc/noy131

3. Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Butowski N, Fenstermaker RA, Forsyth P, Hattangadi-Gluth J, Holdhoff M, Howard S, Junck L, Kaley T, Kumthekar P, Loeffler JS, Moots PL, Mrugala MM, Nagpal S, Pandey M, Parney I, Peters K, Puduvalli VK, Ragsdale J, Rockhill J, Rogers L, Rusthoven C, Shonka N, Shrieve DC, Sills AK, Swinnen LJ, Tsien C, Weiss S, Wen PY, Willmarth N, Bergman MA, Engh A (2017) NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017. *J Natl Compr Canc Netw*. 15(11):1331-1345. https://doi.org/10.6004/jnccn.2017.0166

4. Tanase C, Albulescu R, Codrice E, Popescu ID, Mihai S, Enciu AM, Cruceru ML, Popa AC, Neagu Al, Necula LG, Mambet C, Neagu M (2015) Circulating biomarker panels for targeted therapy in brain tumors. *Future oncology (London, England)*. 11(3):511-524. https://doi.org/10.2217/fon.14.238

5. Zhao Z, Zhao X, Lu J, Xue J, Liu P, Mao H (2018) Prognostic roles of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in ovarian cancer: a meta-analysis of retrospective studies. *Archives
of gynecology and obstetrics.297(4):849-857. https://doi.org/10.1007/s00404-018-4678-8
6. Perisanidis C, Psyrri A, Cohen EE, Engelmann J, Heinze G, Perisanidis B, Stift A, Filipits M, Kornek G, Nkenke E (2015) Prognostic role of pretreatment plasma fibrinogen in patients with solid tumors: A systematic review and meta-analysis. Cancer treatment reviews.41(10):960-970. https://doi.org/10.1016/j.ctrv.2015.10.002
7. He J, Pan H, Liang W, Xiao D, Chen X, Guo M, He J (2017) Prognostic Effect of Albumin-to-Globulin Ratio in Patients with solid tumors: A Systematic Review and Meta-analysis. Journal of Cancer.8(19):4002-4010. https://doi.org/10.7150/jca.21141
8. Han S, Liu Y, Li Q, Li Z, Hou H, Wu A (2015) Pre-treatment neutrophil-to-lymphocyte ratio is associated with neutrophil and T-cell infiltration and predicts clinical outcome in patients with glioblastoma. BMC cancer.15(1):617-626. https://doi.org/10.1186/s12885-015-1629-7
9. Xu WZ, Li F, Xu ZK, Chen X, Sun B, Cao JW, Liu YG (2017) Preoperative albumin-to-globulin ratio and prognostic nutrition index predict prognosis for glioblastoma. OncoTargets and therapy.10:725-733. https://doi.org/10.2147/ott.s127441
10. Zadora P, Dabrowski W, Czarko K, Smolen A, Kotlinska-Hasiec E, Wiorkowski K, Sikora A, Jarosz B, Kura K, Rola R, Trojanowski T (2015) Preoperative neutrophil-lymphocyte count ratio helps predict the grade of glial tumor - a pilot study. Neurologia i neurochirurgia polska.49(1):41-44. https://doi.org/10.1016/j.pjnns.2014.12.006
11. Zheng S-H, Huang J-L, Chen M, Wang B-L, Ou Q-S, Huang S-Y (2018) Diagnostic value of preoperative inflammatory markers in patients with glioma: a multicenter cohort study. Journal of neurosurgery.129(3):583-592. https://doi.org/10.3171/2017.3.JNS161648
12. He ZQ, Duan H, Ke C, Zhang XH, Guo CC, Al-Nahari F, Zhang J, Chen ZH, Chen YS, Liu ZG, Wang J, Chen ZP, Jiang XB, Mou YG (2017) Evaluation of cumulative prognostic score based on pretreatment plasma fibrinogen and serum albumin levels in patients with newly diagnosed high-grade gliomas. Oncotarget.8(30):49605-49614. https://doi.org/10.18632/oncotarget.17849
13. Wang P-F, Meng Z, Song H-W, Yao K, Duan Z-J, Yu C-J, Li S-W, Yan C-X (2018) Preoperative Changes in Hematological Markers and Predictors of Glioma Grade and Survival. Front Pharmacol.9:886-892. https://doi.org/10.3389/fphar.2018.00886
14. Singh R, Mishra MK, Aggarwal H (2017) Inflammation, Immunity, and Cancer. Mediators of inflammation.2017:6027305. https://doi.org/10.1155/2017/6027305
15. Song LR, Weng JC, Li CB, Huo XL, Li H, Hao SY, Wu Z, Wang L, Li D, Zhang JT (2020) Prognostic and predictive value of an immune infiltration signature in diffuse lower-grade gliomas. JCI insight.5(8):e133811-e133865. https://doi.org/10.1172/jci.insight.133811
16. Liu M, Wang L (2020) Prognostic significance of preoperative serum albumin, albumin-to-globulin ratio, and prognostic nutritional index for patients with glioma: A meta-analysis. Medicine.99(27):e20927-e20936. https://doi.org/10.1097/md.00000000000020927
17. Xu W, Wang D, Zheng X, Ou Q, Huang L (2018) Sex-dependent association of preoperative hematologic markers with glioma grade and progression. J Neurooncol.137(2):279-287.
18. Yee PP, Wei Y, Kim SY, Lu T, Chih SY, Lawson C, Tang M, Liu Z, Anderson B, Thamburaj K, Young MM, Aregawi DG, Glantz MJ, Zacharia BE, Specht CS, Wang HG, Li W (2020) Neutrophil-induced ferroptosis promotes tumor necrosis in glioblastoma progression. *Nature communications*. 11(1):5424-5445. https://doi.org/10.1038/s41467-020-19193-y

19. Diakos CI, Charles KA, McMillan DC, Clarke SJ (2014) Cancer-related inflammation and treatment effectiveness. *Lancet Oncol*. 15(11):e493-e503. https://doi.org/10.1016/S1470-2045(14)70263-3

20. Shao B, Wahrenbrock MG, Yao L, David T, Coughlin SR, Xia L, Varki A, McEver RP (2011) Carcinoma mucins trigger reciprocal activation of platelets and neutrophils in a murine model of Trousseau syndrome. *Blood*. 118(15):4015-4023. https://doi.org/10.1182/blood-2011-07-368514

21. Seaton K (2001) Albumin concentration controls cancer. *Journal of the National Medical Association*. 93(12):490-493. https://doi.org/pubmed.ncbi.nlm.nih.gov/11800279

22. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. *Carcinogenesis*. 30(7):1073-1081. https://doi.org/10.1093/carcin/bgp127

23. Wang PF, Zhang J, Cai HQ, Meng Z, Yu CJ, Li SW, Wan JH, Yan CX (2019) Sanbo Scoring System, Based on Age and Pre-treatment Hematological Markers, is a Non-invasive and Independent Prognostic Predictor for Patients with Primary Glioblastomas: A Retrospective Multicenter Study. *Journal of Cancer*. 10(23):5654-5660. https://doi.org/10.7150/jca.33047

24. Palumbo JS, Degen JL (2010) Mechanisms coupling the hemostatic system to colitis-associated cancer. *Thrombosis research*. 125 Suppl 2:S39-43. https://doi.org/10.1016/s0049-3848(10)70011-6

25. Steinbrecher KA, Horowitz NA, Blevins EA, Barney KA, Shaw MA, Harmel-Laws E, Finkelman FD, Flick MJ, Pinkerton MD, Talmage KE, Kombrinck KW, Witte DP, Palumbo JS (2010) Colitis-associated cancer is dependent on the interplay between the hemostatic and inflammatory systems and supported by integrin alpha(M)beta(2) engagement of fibrinogen. *Cancer research*. 70(7):2634-2643. https://doi.org/10.1158/0008-5472.can-09-3465

26. Shu YJ, Weng H, Bao RF, Wu XS, Ding Q, Cao Y, Wang XA, Zhang F, Xiang SS, Li HF, Li ML, Mu JS, Wu WG, Liu YB (2014) Clinical and prognostic significance of preoperative plasma hyperfibrinogenemia in gallbladder cancer patients following surgical resection: a retrospective and in vitro study. *BMC cancer*. 14:566. https://doi.org/10.1186/1471-2407-14-566

27. Vuong HG, Nguyen TQ, Ngo TNM, Nguyen HC, Fung KM, Dunn IF (2020) The interaction between TERT promoter mutation and MGMT promoter methylation on overall survival of glioma patients: a meta-analysis. *BMC cancer*. 20(1):897-905. https://doi.org/10.1186/s12885-020-07364-5

Tables

**Table 1: The Summary of Clinical Characteristics of HGGs patients (n=354)**
| Characteristic | G3 (n=59,16.7%) | G4/GBM (n=295,83.3%) | P-value |
|---------------|-----------------|----------------------|---------|
| gender        |                 |                      | 0.737   |
| Female        | 27 (45.8%)      | 128 (43.4%)          |         |
| Male          | 32 (54.2%)      | 167 (56.6%)          |         |
| pEPI          |                 |                      | 0.226   |
| wit-pEPI      | 46 (78.0%)      | 249 (84.4%)          |         |
| ex-pEPI       | 13 (22.0%)      | 46 (15.6%)           |         |
| pKPS          |                 |                      | 0.887   |
| ≤70           | 30 (50.8%)      | 147 (49.8%)          |         |
| ≥70           | 29 (49.2%)      | 148 (50.2%)          |         |
| IDH           |                 |                      | 0.000   |
| IDH-wt        | 21 (35.6%)      | 273 (92.5%)          |         |
| IDH-mut       | 38 (64.4%)      | 22 (7.5%)            |         |
| age/years     |                 |                      | 0.000   |
| mean±SD       | 45.24±13.36     | 53.76±13.32          |         |
| range         | 4-77            | 9-78                 |         |
| PLR           | 138.26±79.69    | 137.18±66.27         | 0.912   |
| NLR           | 2.79±2.24       | 3.46±2.98            | 0.102   |
| MLR           | 0.28±0.10       | 0.30±0.16            | 0.173   |
| FIB           | 2.84±0.65       | 3.08±0.83            | 0.034   |
| ALB           | 42.14±2.66      | 42.14±3.66           | 0.994   |
| GLOB          | 23.68±3.82      | 24.49±4.14           | 0.165   |
| AGR           | 1.83±0.33       | 1.77±0.35            | 0.257   |
| PNI           | 51.82±4.90      | 50.85±4.78           | 0.159   |

HGGs = high-grade gliomas; G3 = WHO Grade III; G4 = WHO Grade IV; GBM = glioblastoma multiforme; pEPI = preoperative epilepsy status; wit-pEPI = without preoperative epilepsy status; ex-pEPI = existence of preoperative epilepsy status; pKPS = preoperative Karnofsky performance status score; IDH = isocitrate dehydrogenase (IDH)-1/2 mutations status; IDH-wt = IDH wild type; IDH-mut = IDH mutant type; SD = standard deviation; PLR = absolute platelet counts/absolute lymphocyte counts ratio; NLR = absolute neutrophil counts/absolute lymphocyte counts ratio; MLR = absolute monocyte counts/absolute
lymphocyte counts ratio; FIB = fibrinogen; ALB = serum albumin; GLOB = serum globulin; AGR = serum albumin/ serum globulin ratio; PNI = albumin (g/L) + 5 * total lymphocyte count (109/L.

Table 2: The Predictive Value of Hematological Indicators in Distinguishing GBM and IDH Molecular Subtypes from HGGs
| Variable | G4/GBM | | G4 IDH-wt | |
|----------|--------|--------|----------|--------|
|          | AUC (95%CI) | P-value | AUC (95%CI) | P-value |
| PLR      | 0.506 (0.427-0.585) | 0.879 | 0.504 (0.435-0.573) | 0.910 |
| NLR      | 0.583 (0.504-0.662) | 0.044 | 0.572 (0.502-0.642) | 0.049 |
| MLR      | 0.512 (0.438-0.586) | 0.772 | 0.505 (0.439-0.572) | 0.888 |
| FIB      | 0.595 (0.519-0.672) | 0.021 | 0.615 (0.546-0.684) | 0.002 |
| ALB      | 0.503 (0.431-0.575) | 0.938 | 0.501 (0.433-0.568) | 0.984 |
| GLOB     | 0.542 (0.465-0.620) | 0.303 | 0.524 (0.454-0.593) | 0.517 |
| AGR      | 0.544 (0.468-0.620) | 0.285 | 0.536 (0.469-0.604) | 0.320 |
| PNI      | 0.525 (0.450-0.600) | 0.552 | 0.519 (0.451-0.587) | 0.605 |
| age+PLR  | 0.702 (0.631-0.773) | 0.000 | 0.722 (0.658-0.786) | 0.000 |
| age+NLR  | 0.711 (0.639-0.784) | 0.000 | 0.723 (0.658-0.788) | 0.000 |
| age+MLR  | 0.709 (0.640-0.777) | 0.000 | 0.720 (0.657-0.783) | 0.000 |
| age+FIB  | 0.712 (0.642-0.783) | 0.000 | 0.726 (0.662-0.791) | 0.000 |
| age+ALB  | 0.700 (0.627-0.772) | 0.000 | 0.707 (0.641-0.772) | 0.000 |
| age+GLOB | 0.698 (0.629-0.767) | 0.000 | 0.708 (0.645-0.771) | 0.000 |
| age+AGR  | 0.703 (0.634-0.772) | 0.000 | 0.720 (0.657-0.783) | 0.000 |
| age+PNI  | 0.703 (0.634-0.773) | 0.000 | 0.722 (0.658-0.785) | 0.000 |
| PLR+NLR  | 0.610 (0.530-0.689) | 0.008 | 0.607 (0.538-0.677) | 0.003 |
| PLR+MLR  | 0.509 (0.435-0.584) | 0.819 | 0.507 (0.441-0.574) | 0.842 |
| PLR+FIB  | 0.594 (0.518-0.670) | 0.023 | 0.614 (0.545-0.683) | 0.002 |
| PLR+ALB  | 0.504 (0.426-0.582) | 0.926 | 0.504 (0.435-0.573) | 0.921 |
| PLR+GLOB | 0.539 (0.461-0.616) | 0.349 | 0.522 (0.452-0.592) | 0.547 |
| PLR+AGR  | 0.535 (0.460-0.611) | 0.389 | 0.533 (0.466-0.600) | 0.364 |
| PLR+PNI  | 0.528 (0.453-0.602) | 0.504 | 0.520 (0.452-0.588) | 0.589 |
| NLR+MLR  | 0.569 (0.490-0.648) | 0.096 | 0.559 (0.490-0.629) | 0.105 |
| NLR+FIB  | 0.604 (0.530-0.677) | 0.012 | 0.618 (0.549-0.686) | 0.001 |
| Combination    | AUC   | SE   | 95% CI          | P    |
|----------------|-------|------|-----------------|------|
| NLR+ALB        | 0.582 | 0.047| 0.503-0.661     | 0.036|
| NLR+GLOB       | 0.578 | 0.058| 0.500-0.657     | 0.108|
| NLR+AGR        | 0.580 | 0.053| 0.502-0.658     | 0.063|
| NLR+PNI        | 0.561 | 0.141| 0.484-0.637     | 0.157|
| MLR+FIB        | 0.600 | 0.015| 0.526-0.674     | 0.002|
| MLR+ALB        | 0.515 | 0.708| 0.441-0.590     | 0.864|
| MLR+GLOB       | 0.548 | 0.241| 0.472-0.625     | 0.515|
| MLR+AGR        | 0.533 | 0.420| 0.458-0.609     | 0.654|
| MLR+PNI        | 0.518 | 0.656| 0.444-0.593     | 0.965|
| FIB+ALB        | 0.596 | 0.020| 0.519-0.672     | 0.001|
| FIB+GLOB       | 0.593 | 0.024| 0.518-0.668     | 0.005|
| FIB+AGR        | 0.595 | 0.022| 0.520-0.670     | 0.002|
| FIB+PNI        | 0.612 | 0.007| 0.537-0.687     | 0.001|
| ALB+GLOB       | 0.542 | 0.305| 0.465-0.620     | 0.519|
| ALB+AGR        | 0.540 | 0.333| 0.462-0.618     | 0.573|
| ALB+PNI        | 0.560 | 0.144| 0.482-0.639     | 0.261|
| GLOB+AGR       | 0.545 | 0.279| 0.466-0.623     | 0.488|
| GLOB+PNI       | 0.552 | 0.207| 0.475-0.629     | 0.239|
| AGR+PNI        | 0.536 | 0.387| 0.461-0.610     | 0.433|

HGGs = high-grade gliomas; G4 = WHO Grade IV; GBM = glioblastoma multiforme; IDH = isocitrate dehydrogenase (IDH)-1/2 mutations status; G4 IDH-wt = WHO Grade IV IDH wild type; AUC = the area under the curve; 95%CI = 95% confidence interval; PLR = absolute platelet counts/absolute lymphocyte counts ratio; NLR = absolute neutrophil counts/absolute lymphocyte counts ratio; MLR = absolute monocyte counts/ absolute lymphocyte counts ratio; FIB = fibrinogen; ALB = serum albumin; GLOB = serum globulin; AGR = serum albumin/ serum globulin ratio; PNI = albumin (g/L) + 5 * total lymphocyte count (10⁹/L).

**Figures**
Figure 1

The comparison of hematology indexes in IDH groups and subgroups. The comparison of NLR(a) and FIB(b) in different IDH groups; (c) The comparison of FIB in different IDH subgroups.

Figure 2

The diagnostic value of hematology indicators in distinguishing GBM from HGGs. the AUC of FIB(a), age+FIB(b), PLR+NLR(c), NLR+FIB(d), MLR+FIB(e), FIB+PNI(f).
Figure 3

The diagnostic value of hematology indicators in distinguishing G4 IDH-wt from HGGs. the AUC of FIB(a), age+FIB(b), PLR+NLR(c), NLR+FIB(d), MLR+FIB(e), FIB+PNI(f).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- SupplementaryMaterial.docx
- FIG.S1.tif